Phase 1 trial outcomes. (A) Total donor chimerism at days +30, +100, and +180 after transplantation in patients without evidence of disease relapse/progression. Donor chimerism analysis was not mandated beyond day +100. The 2 patients with low initial donor chimerism of 54% and 0% had MPD. The protocol was subsequently amended to exclude MPD. (B) Cumulative incidence of grade II-IV acute GVHD and chronic GVHD with graft failure, relapse/progression, and death as competing events. (C) Overall and event-free survival (N = 23). Events include graft failure, relapse/progression, and death. (D) Cumulative incidence of graft failure and relapse/progression with death as a competing event.